Microarray analysis of vascular endothelial growth factor pathway


Rebecca Feldman, Ph.D.1, Zoran Gatalica MD, DSc1, Sandeep Reddy MD1, Krishnansu Tewari, M.D., F.A.C.O.G., F.A.C.S.2

Objectives: On August 14, 2014, the US Food & Drug Administration approved bevacizumab for advanced cervical cancer based on Gynecologic Oncology Group (GOG) protocol 240, the randomized phase 3 clinical trial which demonstrated significantly improved overall survival with chemotherapy plus bevacizumab compared to chemotherapy alone. Although the signal for efficacy of bevacizumab was not observed in a subgroup analysis of prognostic factors for ACs, this histologic type comprised only 20% of the GOG 240 population. We sought to determine whether VEGF pathway
biomarkers were differentially expressed between SCCA and AC of the cervix.

Download Publication